English   español  

Browsing by Author Mateos, Maria Victoria

Showing results 1 to 20 of 35  next >
RightsPreviewIssue DateTitleAuthor(s)Type
closedAccessaccesoRestringido.pdf.jpg2010BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML)Santamaría, Carlos; Chillón, Maria del Carmen; García-Sanz, Ramón; Caballero, Dolores; Mateos, Maria Victoria; Sarasquete, María Eugenia; Díaz-Mediavilla, J.; San Miguel, Jesús F.; González, MarcosArtículo
closedAccessaccesoRestringido.pdf.jpg2007Bortezomib in multiple myelomaMateos, Maria Victoria; San Miguel, Jesús F.Artículo
closedAccessaccesoRestringido.pdf.jpg2011Bortezomib in the upfront treatment of multiple MyelomaSan Miguel, Jesús F.; Mateos, Maria VictoriaCapítulo de libro
openAccessBortezomib Plus Melphalan.pdf.jpg2010Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA TrialMateos, Maria Victoria; San Miguel, Jesús F.Artículo
openAccessBortezomib plus.pdf.jpg2008Bortezomib plus melphalan and prednisone for initial treatment of multiple myelomaSan Miguel, Jesús F.; Mateos, Maria VictoriaArtículo
openAccess10.3324-haematol.2010.028027.pdf.jpg1-Nov-2010Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 studyLahuerta, Juan José; Mateos, Maria Victoria; San Miguel, Jesús F.Artículo
openAccessCan multiple myeloma.pdf.jpg2011Can multiple myeloma become a curable disease?San Miguel, Jesús F.; Mateos, Maria VictoriaArtículo
closedAccessaccesoRestringido.pdf.jpg2011Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: Analysis of the VISTA trialRichardson, Paul G.; Mateos, Maria Victoria; San Miguel, Jesús F.Artículo
closedAccessaccesoRestringido.pdf.jpg2012Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patientsPaiva, Bruno; Gutiérrez, Norma Carmen; Chen, Xi; Vidriales, Belén; Martínez-López, Joaquín; Mateos, Maria Victoria; López-Corral, L.; Díaz-Rodríguez, Elena; Orfao, Alberto; Lahuerta, Juan José; Bladé, Joan; Pandiella, Atanasio; San Miguel, Jesús F.Artículo
closedAccessaccesoRestringido.pdf.jpg2011Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myelomaPaiva, Bruno; Pérez-Andrés, Martin; Almeida, Julia; Mateos, Maria Victoria; López-Corral, L.; Gutiérrez, Norma Carmen; Schmidt-Hieber, M.; Lahuerta, Juan José; San Miguel, Jesús F.; Orfao, AlbertoArtículo
closedAccessaccesoRestringido.pdf.jpg2011Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. Melphalan-prednisone in the phase III VISTA trial in multiple myelomaDelforge, Michel; Mateos, Maria Victoria; San Miguel, Jesús F.Artículo
closedAccessaccesoRestringido.pdf.jpg2005Genetic abnormalities and patterns of antigenic expression in multiple myelomaMateo, Gema; Castellanos, Mariana V.; Rasillo, Ana; Gutiérrez, Norma Carmen; Hernández, Jesús M.; López-Borges, Susana; Bladé, Joan; Mateos, Maria Victoria; Díaz-Mediavilla, J.; Pandiella, Atanasio; Lahuerta, Juan José; Orfao, Alberto; San Miguel, Jesús F.Artículo
closedAccessaccesoRestringido.pdf.jpg2012High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myelomaPaiva, Bruno; Gutiérrez, Norma Carmen; Vidriales, Belén; Martínez-López, Joaquín; Mateos, Maria Victoria; Díaz-Mediavilla, J.; Lahuerta, Juan José; Bladé, Joan; San Miguel, Jesús F.Artículo
closedAccessaccesoRestringido.pdf.jpg2009International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)Giralt, S.; San Miguel, Jesús F.; Mateos, Maria VictoriaArtículo
closedAccessaccesoRestringido.pdf.jpg2011Long-term prognostic significance of response in multiple myeloma after stem cell transplantationMartínez-López, Joaquín; Mateos, Maria Victoria; San Miguel, Jesús F.Artículo
closedAccessaccesoRestringido.pdf.jpg2012Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trialMateos, Maria Victoria; Martínez-López, Joaquín; Gutiérrez, Norma Carmen; García-Sanz, Ramón; Lahuerta, Juan José; Bladé, Joan; San Miguel, Jesús F.Artículo
closedAccessaccesoRestringido.pdf.jpg2012Management of treatment-emergent peripheral neuropathy in multiple myelomaRichardson, Paul G.; Lahuerta, Juan José; Mateos, Maria Victoria; Bladé, Joan; San Miguel, Jesús F.Artículo
closedAccessaccesoRestringido.pdf.jpg2008Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantationPaiva, Bruno; Vidriales, Belén; Mateo, Gema; Gutiérrez, Norma Carmen; Mateos, Maria Victoria; Orfao, Alberto; San Miguel, Jesús F.Artículo
closedAccessaccesoRestringido.pdf.jpg2012Multiple myeloma: Treatment evolutionSan Miguel, Jesús F.; Mateos, Maria Victoria; Ocio, Enrique M.; García-Sanz, RamónArtículo
openAccess2012Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?Matarraz, Sergio; Paiva, Bruno; Díez-Campelo, María; López-Corral, L.; Mateos, Maria Victoria; Hernández, M. Teresa; San Miguel, Jesús F.; Orfao, AlbertoArtículo